The U.S. Food and Drug Administration (FDA) announced that it will hold a hybrid meeting of the Microbiology Devices Panel of the Medical Devices Advisory Committee on November 19, 2026, to discuss the use of pathogen-agnostic sequencing in public health emergency preparedness and response efforts. The discussion may include local or national outbreaks, whether caused by known pathogens or by agents not previously identified.
The meeting will take place from 9 a.m. to 4 p.m. Eastern Time, in person at the FDA campus in Silver Spring, Maryland, with online participation available. The session will be broadcast on YouTube, and the meeting will be open to the public.
What Will the Committee Examine?
The committee will provide recommendations to the FDA on the scientific, clinical, and public health dimensions associated with these uses, as well as implementation opportunities and obstacles that may affect test development. Specific topics include test design and how to establish a flexible, effective, and validated bioinformatics system capable of addressing frequent changes in genetic sequences.
The discussion is being held, in part, to fulfill a requirement in the Food and Drug Administration and Drug Administration Reform Act of 2022 (FDORA). Holding the meeting does not mean that a regulatory decision will be issued or that a particular test will be approved; advisory committees provide nonbinding scientific advice, and although the FDA may generally follow their recommendations, it is not legally required to do so.
What Is Changing in Practice?
The meeting is significant because it focuses on the scientific and operational infrastructure required to use sequencing as an emergency preparedness tool, rather than limiting the discussion to a test directed at a pathogen known in advance. The agenda indicates that the validity of these tools depends not only on reading the sequence, but also on test design and the ability of bioinformatics systems to keep pace with changing genetic data and validate results.
For diagnostic device developers and public health authorities, the meeting provides an opportunity to discuss requirements and challenges before future coordination priorities take shape. For the public and researchers, the comment process offers a way to submit feedback that may be considered by the committee or the FDA, without automatically becoming a regulatory decision.
Participation Deadlines
The FDA has established a public comment docket under FDA-2026-N-8692. The docket will close on November 12, 2026, at 11:59 p.m. Eastern Time through Regulations.gov. Paper comments, hand-delivered comments, or comments submitted by delivery services will also be considered timely if they arrive on or before that date.
Comments received by November 3 at the latest will be made available to the committee before the meeting, while the FDA will consider later comments. It remains necessary to check the agency’s website before attending, as last-minute changes to the meeting may occur. The FDA also requests contact at least seven days in advance to request disability-related accommodations.